Morepen Laboratories Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹746 Cr +81.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
ML

Morepen Laboratories Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Morepen Laboratories Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹485Cr
+4.1% YoY
+0.2% QoQ
Net profit
₹16Cr
−20% YoY
−42.9% QoQ
Margin
5%
−4 pp YoY
−5 pp QoQ

Based on Morepen Laboratories Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹117
Market cap₹6.6K Cr
P/E56.4

The short version

Q4 FY26 revenue: Rs. 472 crore, up 22% year-on-year (YoY) from Rs. 385 crore in Q4 FY25 (Page 12, 5). Q4 FY26 EBITDA: Rs. 33 crore, up 24% YoY (Page 12).

From Morepen Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q4 FY26 revenue: Rs. 472 crore, up 22% year-on-year (YoY) from Rs. 385 crore in Q4 FY25 (Page 12, 5)
  • API segment Q4 growth: 17% YoY (Page 5)
  • Medical Devices segment Q4 growth: 31% YoY (Page 5)
  • FY26 total revenue growth: 8% YoY, Rs. 597 crore reported (Page 10, 5)
  • Gross revenue FY25: Rs. 1570 crore; FY26 forecast: Rs. 1703 crore, implying 8-9% growth (Page 13)
  • Q4 FY26 EBITDA margin about 6.8%; FY26 EBITDA 10.8% (Page 12, 13)
  • Outlook: Long-duration manufacturing programs started Q4 FY26 expected to progressively support operating leverage and growth (Pages 12, 13)

2 more points from Morepen Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Manufacturing capacity expansion planned from existing ~500 KL production base to ~800 KL (mid-term) and ~1000 KL (long-term).
  • Focus on long-duration supply programs to improve operating leverage and stable recurring revenues.
  • CDMO & Manufacturing: Audits and validation batches completed; commercial production commenced; phased delivery schedule received, starting Q4 FY26.
  • Building 20% ‘ready capacity’ to onboard new customers and developing speciality portfolio for select clients.
  • Status: Commercial supplies under long-duration manufacturing programs began in Q4 FY26.

2 more points from Morepen Laboratories Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The presentation reports that Morepen Laboratories Limited has secured a multi-year mandate worth Rs. 823 crore under its commercial program milestones (Page 3).
  • It mentions that commercial production has commenced and phased delivery is scheduled to start in the coming weeks (Page 3).
  • On Page 13, it is stated that Q4 FY26 marked the commencement of commercial supplies under long-duration manufacturing programs, indicating progress in order fulfillment.
  • The focus is on the secured multi-year mandate, commencement of commercial production, and transition toward long-duration supply contracts with stable recurring revenues.

Morepen Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Morepen Laboratories Ltd Q4 FY26 results — key figures

Morepen Laboratories Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue485466+4.1%484+0.2%
Operating profit (EBITDA)2442-42.9%46-47.8%
Operating margin5%9%-4 pp10%-5 pp
Profit before tax2326-11.5%35-34.3%
Net profit (PAT)1620-20%28-42.9%
EPS (₹)0.290.37-21.6%0.50-42%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Morepen Laboratories Ltd Q4 FY26 results?

Q4 FY26 revenue: Rs. 472 crore, up 22% year-on-year (YoY) from Rs. 385 crore in Q4 FY25 (Page 12, 5). Q4 FY26 EBITDA: Rs. 33 crore, up 24% YoY (Page 12).

What is Morepen Laboratories Ltd share price analysis?

Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.

Is Morepen Laboratories Ltd planning capital expenditure?

Manufacturing capacity expansion planned from existing ~500 KL production base to ~800 KL (mid-term) and ~1000 KL (long-term).

Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.